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Abstract Newborn infants experience acute pain with
various medical procedures. Evidence demonstrates that
controlling pain in the newborn period is beneficial,
improving physiologic, behavioral, and hormonal out-
comes. Multiple validated scoring systems exist to assess
pain in a neonate; however, there is no standardized or
universal approach for pain management. Healthcare
facilities should establish a neonatal pain control program.
The first step is to minimize the total number of painful
iatrogenic events when possible. If a procedure cannot be
avoided, a tiered approach to manage pain using environ-
mental, non-pharmacologic, and pharmacologic modalities
is recommended. This systematic approach should decrease
acute neonatal pain, poor outcomes, and provider and
parent dissatisfaction.
Keywords Neonatal  Pain management  Glucose and
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Introduction
Newborn infants experience pain just as older children and
adolescents experience pain; however, clinicians’ ability
and approach to assessing and managing neonates is
inadequate and controversial. Newborn infants experience
acute measurable physiologic, behavioral, metabolic, and
hormonal responses to pain [1••, 2]. They also experience
long-term effects, including negative effects on neurologic
and behavioral development. This is because the experi-
ence of pain occurs during a critical time of neurologic
maturation [2]. In fact, preterm infants have demonstrated
an exaggerated acute response to pain and worse behav-
ioral and sensory long-term outcomes when compared to
term neonates [3, 4]. Surmounting evidence demonstrates
that controlling pain in the newborn period is beneficial,
improving physiologic, behavioral, and hormonal out-
comes [1••, 2].
So, why does it remain controversial? Assessing pain in
a neonate is difficult as they are non-verbal and though
multiple validated pain scoring systems exist; there is no
standardized or universal approach to assessing neonatal
pain. Additionally, there appears to be a lack of under-
standing of how neonates perceive pain and the resulting
adverse sequelae that occur when pain remains untreated
[2]. Thus, the use of pain control for neonates undergoing
procedures is limited and inadequate [5, 6]. Further, until
recently, there have been limited data on analgesia effec-
tiveness and safety profiles.
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In 2006, the American Academy of Pediatrics and the
Canadian Pediatric Society published a policy stating that
each healthcare facility should establish a neonatal pain
control program aimed at routine assessment of pain,
reduction in the number of painful procedures, and also
reduction and prevention of acute pain from invasive
procedures [7]. Most scientific literature regarding pain
management and control is from the Neonatal Intensive
Care Unit (NICU) where neonatal pain is commonly
observed. In 2009, an Italian panel of expert neonatolo-
gists, Lago et al. established guidelines to assist clinicians
with management of pain experienced by patients within
the NICU [1••]. Neonates interface with clinicians outside
of the NICU and thus potentially experience painful
procedures within other venues as well. This includes the
newborn nursery, outpatient clinics, the emergency
department and the pediatric ward of the hospital. How-
ever, there have not yet been guidelines addressing pain
assessment or management within these arenas. This
review will explore the methods for assessing pain, the
importance of establishing a universal approach for
assessing pain as well as providing a tiered approach to
managing pain in the neonate. Our goal is to improve pain
scores (patient satisfaction), parental satisfaction, and
provider satisfaction in all venues in which neonates are
evaluated and treated.
Pain Assessment–Pain Scales
Pain assessment in the non-verbal child and neonate can be
a very challenging task in an already subjective process.
There are pain scales used to assess pain; however, there
are variations in the methods and scales used, and there is
not a universal method to assess pain in this population.
Objective measurements including heart rate, blood pres-
sure, and salivary cortisol can be used, but most care
providers usually rely on grimace, crying, and overall
demeanor.
In addition to differences in pain scales, there are myriad
of other factors that may influence perception and evalua-
tion of pain. There is a demonstrable relationship between
anxiety and pain perception in children as well as adults [8,
9••]. It is difficult, for example, to assess the impact of the
often foreign and stressful nature of being in an emergency
department or in an exam room. Another potentially
powerful factor may be the dynamics of the parent–child
relationship and the degree of stress the parent experiences
when their child needs a painful procedure, which may be
perceived by the child and lead to increased anxiety for the
patient. Another often perhaps overlooked factor in the
assessment of pain is the clinician’s skill and willingness to
assess and interpret signs of pain. Studies demonstrate that
there are significant differences between provider’s level of
training and experience in the recognition of pain [10–12].
The Joint Commission standards for hospitalized
patients make pain assessments mandatory for all patients
[13]. The standard numeric 0–10 pain scale may be useful
in verbal children; however, there are scales that have been
validated for use in children as young as three for pain
reporting [14–17]. The revised FACES pain scale, the
Wong-Baker Faces scale, and the 10-cm visual analog
scale are used in many healthcare settings to assess a
pediatric patient’s pain [15, 17–22]. In addition to assess-
ing pain by physiologic parameters in the neonatal popu-
lation, there are multiple validated pain scales utilized by
NICUs to assess pain. For example for term neonates: the
neonatal infant pain scale (NIPS); neonatal facial coding
system (NFCS); neonatal pain, agitation, and sedation scale
(N-PASS); cry, required oxygen, increased vital signs,
expression, sleeplessness scale (CRIES); COMFORT
Scale; and Douleur Aigue Nouveau-ne (DAN) scoring
system have all been described in the literature (see
Table 1). The premature infant pain profile (PIPP) is a
validated pain scoring system for preterm neonates [2, 17].
For infants, non-verbal young children, and in patients with
cognitive impairment, the face, legs, activity, crying, and
consolability (FLACC) scale or the revised FLACC scale
can be used [23–30].
It is important to note that there are no validated or
widely studied scales to assess pain outside of the hospital
setting. Studies regarding pain perception at home and
familiar environments may provide more information
regarding the role of the environment in a patient’s per-
ception of pain. Furthermore, it may elicit information
regarding the dynamic parent–child relationship and the
complexity of a parent’s own perception of their child’s
pain, their comfort with the hospital setting, and their own
past experiences with pain and the hospital setting.
Management of Neonatal Pain: A Tiered
Approach
Neonatal pain is best managed using a multi-directional
approach which can be conceptualized in a tiered manner
(see Fig. 1) and includes non-pharmacologic and pharma-
cologic modalities (see Table 2). The foundational basis for
optimizing pain management in the neonatal population is
aimed at reducing the total number of painful events [31].
This has been well established as a fundamental interven-
tion employed in the NICU, where painful procedures are
performed regularly. How can clinicians reduce the number
of painful events? As noted in Fig. 1, at baseline, the
approach should include avoiding unnecessary painful
procedures. Further, clinicians should reduce the number of
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Table 1 Summary of neonatal pain scales [1]
Pain scale What variables are included? Type of pain Notes
PIPP (premature infant pain
profile)
Heart rate, oxygen saturation, facial actions Procedural,
postoperative
Reliable, valid, clinical utility is
well established
NIPS (neonatal infant pain
score)
Facial expression, crying, breathing
patterns, arm and leg movements, arousal
Procedural Reliable, valid
NFCS (neonatal facial coding
system)
Facial actions Procedural Reliable, valid, clinical utility is
well established, high degree of
sensitivity to analgesia
N-PASS (neonatal pain,
agitation and sedation scale)
Crying, irritability, facial expression,





Reliable, valid. Includes sedation
end of scale, does not distinguish
pain from agitation
CRIES (cry, requires oxygen,
increased vital signs,
expression, sleeplessness)
Crying, facial expression, sleeplessness,
requires oxygen to stay at[95 %
saturation, increased vital signs
Postoperative reliable, valid
COMFORT scale Movement, calmness, facial tension,
alertness, respiration rate, muscle tone,
heart rate, blood pressure
Postoperative, critical
care
Reliable, valid, clinical utility well
established
DAN (Douleur Aigue¨ du
Nouveau-ne´)

















-Oral Sucrose or Glucose
-Breast or Bottle Feeding





Deep Sedation or Anesthesia 
Avoid painful procedures 
Anticipate need of future studies 
Use non-invasive monitoring (NIRS, oxygen saturation, EtCO2 monitoring, transcutaneous bilirubin) 
Heelstick, Fingerstick, Adhesive Removal, Dressing Change, Wound Treatment, Venipuncture, 
Arterial puncture, Subcutaneous Injection, Intramuscular Injection, Peripheral IV Cannulation, 
Removal of PIV, Central Line Placement, Gastric Tube Insertion, Bladder Catheterization, Tracheal 
Extubation, Lumbar Puncture, Peripheral Arterial Line, PICC Line Placement, Circumcision, Chest 
Tube Insertion
Wound Treatment, Venipuncture, Arterial puncture, Subcutaneous Injection, 
Intramuscular Injection, Peripheral IV Cannulation, Central Line Placement, Lumbar 
Puncture, Peripheral Arterial Line, PICC Line Placement, Circumcision, Chest Tube 
Insertion
Heelstick, Fingerstick, Adhesive Removal, Dressing Change, 
Wound Treatment, Venipuncture, Arterial puncture, Circumcision
Wound Treatment, Incision and Drainage, 
Lumbar Puncture, Peripheral Arterial Line, PICC 
Line Placement, Circumcision, Chest Tube 
Insertion
References for this figure: See References: See 1,2,36,37,50-53.
Wound Treatment, Incision and 
Drainage, Lumbar Puncture, Tracheal 
Intubation, Chest Tube Insertion, 
Central Line Placement, 
A Tiered Approach to Analgesia in the 
Neonate 
Fig. 1 A tiered approach to analgesia in the neonate
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bedside interruptions and daily examinations, if possible.
Additionally, clinicians can anticipate the need for future
studies and, with thoughtful planning, can coordinate
studies to minimize the frequency of blood draws [7].
Although a painful procedure within itself, painful blood
draw frequency can further be reduced by insertion of
arterial catheter or central venous line, if there is a need
for more than three lab draws within 1 day [7]. Another
way to reduce painful procedures is to use non-invasive
monitoring when clinically relevant and when resources
are available. These include near infrared spectroscopy
(NIRS) monitoring, oxygen saturation monitoring, and
obtaining bilirubin levels via transcutaneous bilirubi-
nometer [1].
After laying the foundation for neonatal pain manage-
ment, one can escalate therapy based on the degree of
anticipated procedural pain, advancing through the appro-
priate tiers of therapy to achieve optimal analgesia in-
cluding non-pharmacologic and pharmacologic modalities
(see Table 2).






Oral: 20–30 % solution
Multiple doses are more effective
than single [38]
Optimal Dose has not yet been identified










Topical: 0.5–1 g covered with
occlusive dressing 9 45–60 min
Max dose = 1 g
Not recommended for heel lance; more painful, longer
procedure duration












Oral: 10 mg/kg q6 h or 15 mg/kg
q8 h [64]
Rectal: 20–25 mg/kg
IV: loading dose: 20 mg/kg, then
maintenance with [56]
TDD: 37–42 weeks = 50–60 mg/
kg/day
1–3 months = 60–75 mg/kg/day
Neonates have slower clearance than older children [64]
Rare SE: Hepatotoxicity, Renal Toxicity





SQ and IM: 3–5 mg/kg/dose of 0.5 %
(5 mg/mL) or 1 % (10 mg/mL)
[54]
Toxicity: arrhythmias, seizures
Avoid combination with epinephrine in neonates-to minimize
risk of arrhythmia and tissue necrosis











Morphine IV: 0.05–0.1 mg/kg/dose
[75]
SE: Hypotension in preterm neonates [63, 65]
Fentanyl IM/IV: 0.5–1 lg/kg/dose
[75]
Fentanyl intranasal: 1.5–2 lg/kg/dose
[76]
SE: bradycardia, chest wall rigidity [70], but less hypotension,




IM/IV: 0.5–2 mg/kg/dose Bronchodilator: improves ventilation
Minimal effects on respiratory drive, HR, BP
Toxicity:[2 mg/kg/dose bradycardia [73];[5 mg/kg/dose
decreased BP [74]
TDD total daily dosing; SE side effects
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Tier 1: Non-pharmacologic Therapies
The first tier is aimed at employing non-pharmacologic
therapies, which include oral sucrose or glucose, breast or
bottle feeding, skin-to-skin care (aka Kangaroo Care),
swaddling or facilitated tucking, non-nutritive sucking, and
sensorial saturation. Of all non-pharmacologic therapies,
the most robust literature is regarding the use of oral
sucrose.
Oral Sucrose
How do sugars affect pain? The proposed hypothesis is that
glucose (and its alternative forms, such as sucrose) causes
endogenous opioid release, through an unknown mecha-
nism [32–34]. In a systematic review, Stevens et al.
established that in the neonatal population, sucrose sig-
nificantly reduces pain associated with procedures [35].
While the reported outcomes varied among the studies
included in this meta-analysis, patients receiving sucrose
were found to have significant reductions in behavioral and
physiologic indicators of pain, as well as improvements on
several different validated pain scores [35]. Specifically,
measures of physiologic response, such as changes in heart
rate, oxygen saturation, and vagal tone, were dampened
when compared to placebo [35]. The use of sucrose in
neonates, when compared to breast milk or pacifier use, has
also been associated with a reduction in behavioral indi-
cators of pain, such as crying and grimacing during painful
procedures [35].
Glucose, in 20–30 % solutions, has similarly been
studied as an effective alternative to sucrose therapy [36].
Glucose is recommended for venipuncture and heel lancing
procedures, demonstrating a reduction in Premature Infant
Pain Profile (PIPP) scores and the duration of crying in
neonates [36]. In a recent systematic review, Bueno
demonstrated that there has been no significant difference
between the effectiveness of sucrose as compared to glu-
cose [36]. Glucose has not yet been found to provide
appropriate analgesia following more invasive or longer
procedures, such as circumcision or eye examination for
retinopathy of prematurity [36].
In studying their pharmacologic properties, glucose and
sucrose have an ideal safety profile with limited side effects
[36]. The recommended dosing ranges from 12 to 120 mg
(24 % sucrose solution or 20–30 % glucose solution) [35–
39]. It should be noted that the use of less-concentrated
solutions is recommended in premature infants, as higher
osmolar solutions (24–33 % sucrose/glucose) are thought
to be associated with adverse outcomes [i.e., increased risk
of necrotizing enterocolitis (NEC)] [1]. Providing sucrose
in multiple doses, both before and after painful procedures,
such as heel lancing, is more effective than a single dose
[1]. It should also be noted that sucrose or glucose for
analgesia is typically not effective after 3 months of age
[2].
Breastfeeding or Breast milk
If a patient is undergoing a single painful procedure, an
alternative to use of sucrose or glucose or no intervention,
is the use of breastfeeding or breast milk. Shah et al.
demonstrated in a Cochrane review that breastfeeding
appears to have an advantage for one-time painful proce-
dures [40]. Neonates who were breastfed during heelstick
procedures and venipunctures showed a significant
decrease in the variability of physiologic response as
compared to swaddling, holding by mother, placebo,
pacifier use, or oral sucrose [40]. The physiologic param-
eters measured demonstrated a lower increase in heart rate,
reduced duration of total crying time and also reduced the
time to first cry [40]. Further, Shah demonstrated that there
was significant reduction in standardized pain measures,
such as PIPP scores, Douleur Aigue¨ du Nouveau-ne´ (DAN)
scores, neonatal infant pain scale (NIPS), and neonatal
facial coding system (NFCS) scores [40]. Supplemental
breast milk in lieu of breastfeeding was also analyzed in
this systematic review, with variable results. In regard to
physiologic parameters, the outcomes were favorable, as
there was less of an increase in heart rate and decreased
duration of total crying time [40]. Shah also notes a
reduction in NFCS scores, as compared to the placebo
group. However, when evaluated in comparison to NIPS
and DAN, both validated scoring systems, there was no
significant reduction in pain scores with supplemental
breast milk. Is sucrose better? In Shah’s systematic review,
sucrose, when compared to supplemental breast milk,
demonstrated a greater reduction in physiologic parameters
(reduced crying duration and lower heart rate variability)
[40].
Other Non-pharmacologic Therapies: Skin-to-Skin
Contact, Positioning, and Non-nutritive Sucking
In the neonatal population, other environmental interven-
tions have demonstrated effective reduction in pain, par-
ticularly when used as adjunctive therapy to sweet
solutions and/or breastfeeding. Skin-to-Skin contact
involves direct physical contact with the parent and baby
and is also commonly known as Kangaroo Care for the
close resemblance to marsupials’ approach to caring for
their young. Skin-to-Skin contact is effective at reducing
pain, in both physiologic parameters as well as reduction in
PIPP scores [41]. Careful positioning such as swaddling a
Curr Emerg Hosp Med Rep (2016) 4:1–10 5
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neonate and facilitated tucking, which involves manually
flexing a neonate’s arms and the legs, both foster self-
soothing behaviors and are effective at reducing pain in
neonates [41]. Non-Nutritive Sucking has also been eval-
uated in preterm and term infants and is effective at
reducing pain [42]. Non-nutritive sucking has been shown
to have lower variability in heart rate and decreased crying
time duration when compared to swaddling alone, no
intervention, or rocking alone [43, 44]. Although these
environmental measures reduce the pain associated with
procedures, they are not as effective as when used in
combination with other non-pharmacologic therapies.
Combo of Non-pharmacologic Therapies Provides
Synergistic Effect
The use of sucrose or glucose has the best effectiveness
when used in combination with other non-pharmacologic
therapies [36, 45]. Glucose or sucrose when used in com-
bination with non-nutritive sucking reduces pain in neo-
nates [36, 45]. Sensorial saturation, another method of pain
reduction, involves multisensorial stimulation, including
tactile, gustatory, auditory, and visual stimulation. Senso-
rial saturation used in combination with oral sucrose or
glucose has been shown to even further reduce pain asso-
ciated with minor painful procedures (i.e., lab draws) [46,
47]. For example, this would incorporate placing a sugary
solution on the infant’s tongue and then providing a gentle
facial massage while speaking calmly to the infant [46, 47].
Facilitated tucking is less effective than sucrose, however,
when used in combination with sugary solutions has also
demonstrated a synergistic effect [48]. Breastfeeding in
combination with the use of glucose or sucrose has also
demonstrated a reduction in pain compared to either indi-
vidually [49]. Skin-to-Skin contact when used with glucose
or sucrose reduces neonatal pain associated with minor
procedures more than compared to either individually [50].
Thus, when feasible and appropriate resources are avail-
able, for single minor painful procedures, clinicians should
aim to use combination of environmental and non-phar-
macologic methods to achieve optimal analgesia.
Tier 2–5: Pharmacologic Management
Tier 2: Topical Anesthetics
Following the tiered approach to neonatal pain manage-
ment, as noted in Fig. 1, Tier 2 involves the use of topical
anesthetics. Multiple formulations of topical anesthetics are
available for use in the pediatric population, including
lidocaine 2.5 %/prilocaine 2.5 % (EMLA), tetracaine
cream 2 % (Ametop, or Pontocaine), liposomal
lidocaine 4 % (LMX-4) or liposomal lidocaine 5 %
(LMX-5), lidocaine 7 %/tetracaine 7 % (S-caine), and
benzocaine. However, most research in the neonatal pop-
ulation has been conducted with EMLA. The use of
Ametop or Pontocaine, LMX-4, LMX-5, and S-caine
cannot be recommended for use in the neonatal population
because safety and effectiveness have not yet been estab-
lished [51, 52].
Topical benzocaine, an over-the-counter formulation for
teething pain, should also be used with caution, as the high
concentration of benzocaine (20 % = 200 mg/mL) can
easily lead to overdose. Toxicity of these products can lead
to multiple adverse effects, including methemoglobinemia
and life-threatening arrhythmias, so caution should be used
when choosing the appropriate topical anesthetic [51, 53].
The American Academy of Pediatrics does not recommend
the use of topical anesthetics, specifically lidocaine or
benzocaine, for teething pain because they have been
associated with significant morbidity (seizures, respiratory
depression, arrhythmias) and even death, but recommends
using a teething ring (chilled but not frozen) and/or a gentle
massage of the gums by the parent/caregiver. The FDA has
also issued a black box warning against using over-the-
counter topical anesthetics for teething pain [53].
Although many formulations of topical anesthetic are
available, EMLA has been well established as effective in
the neonatal population for reducing pain associated with
minor procedures. EMLA is a eutectic mixture of lidocaine
(2.5 %) and prilocaine (2.5 %) in a cream base. EMLA
should be recommended for use in circumcision and
venipuncture. With circumcisions, EMLA decreased facial
grimacing, the total duration of crying time, heart rate
variability, and oxygen desaturations when compared to
placebo [54]. When performing venipuncture, it is recom-
mended that clinicians use EMLA, as it reduces pain [51].
EMLA should also be used for analgesia with lumbar
punctures, as it reduced heart rate variability, facial gri-
macing, and oxygen desaturations when compared to pla-
cebo [52]. Taddio notes equivocal results with pain
reduction during peripherally inserted central catheter
(PICC) line placement, but clinicians should still consider
its use [51]. EMLA is not recommended for heelstick
procedures because it is ineffective at reducing pain and
may actually prolong the procedure [1, 51]. The recom-
mended dose is 0.5 g to 1.0 g (maximum dose) applied to
procedural site. This should be covered with an occlusive
dressing for 45–60 min prior to procedure, which connotes
necessity of non-emergent procedures [1]. EMLA has
demonstrated effective safety profile; however, rare but
serious side effects, such as methemoglobinemia, can
occur. Methemoglobinemia is more likely in patients with
underlying G6PD Deficiency or following excessive doses
[51]. A common side effect of EMLA is transient skin
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irritation, which can occur with any of the topical anes-
thetics [51, 52].
Tier 3: Acetaminophen
Acetaminophen is one of the most commonly used sys-
temic medications in the neonatal population due to its
well-established effectiveness at pain reduction as well as
its favorable side effect profile. Acetaminophen is recom-
mended for use in mildly to moderately painful procedures
such as heelsticks, fingersticks, adhesive removal, dressing
changes, wound treatment, venipuncture, arterial puncture,
and circumcision [1, 51, 52, 55, 56]. There are various
formulations, which have different dosing and clearance
patterns, particularly in neonates. Oral acetaminophen
should be dosed between 10 mg/kg every 6 h or 15 mg/kg
every 8 h [56]. Neonates have slower clearance as com-
pared to older children, so clinicians should be aware to
dose less frequently [56]. There are limited data available
for the use of IV acetaminophen in neonates, but recom-
mended doses are loading dose of 20 mg/kg and then
maintenance therapy administering 10 mg/kg every 6 h
[57]. Total daily doses for neonates less than 1 month of
age born between 37 and 42 weeks gestation is 50–60 mg/
kg/day and is 60–75 mg/kg/day for infants 1–3 months
postnatal age [58•]. Rectal acetaminophen should be dosed
at 20 mg/kg every 6–8 h [57]. Acetaminophen in low doses
is safe for use in neonates, but rare side effects should be
noted including hepatic and renal toxicity [59, 60]. Acet-
aminophen is also helpful when used in combination with
morphine. This combination has minimal adverse effects
and reduces the total dose requirement of morphine to
achieve equivalent pain reduction [61, 62•].
NSAIDS have well-established adverse effects in the
neonatal population and are not recommended for use in
the neonatal population [63]. Typically, use can begin for
infants older than 6 months.
Tier 4: Local Anesthetics
Traditional local anesthetics have been well established as
effective in providing analgesia associated with painful
procedures. This represents Tier 4 in the approach to
neonatal analgesia. Lidocaine injections can safely reduce
pain associated with PICC line, arterial line, central venous
line placement, lumbar puncture, and circumcision. As
noted with other measures, the use of lidocaine injections is
most effective when used in combination with other
interventions. For optimal pain relief with circumcision,
sucrose use throughout the procedure and acetaminophen
use for post-procedural pain was most effective [55]. In
neonates, the recommended dose is 0.5 % (5 mg/mL) or
1 % (10 mg/mL) solution to a maximum dose of 3–5 mg/
kg [55]. Again, as with EMLA, in higher doses, there is
risk of arrhythmia and seizures when approaching toxic
doses. Clinicians should avoid combination with epi-
nephrine in neonates, to minimize the risk of arrhythmia
and also tissue necrosis. It should also be noted that needle
free formulations of lidocaine injections (J-Tip) have not
been adequately studied in newborns [64].
Tier 5: Deep Sedation
Opiates
The most commonly used opiates in the neonatal period are
morphine and fentanyl. These systemic analgesics are
typically reserved for moderately to severely painful pro-
cedures and should be adequately titrated accordingly.
Such procedures include wound treatment, incision and
drainage, lumbar puncture, tracheal intubation, chest tube
insertion, and central line placement [1]. Much of the
available evidence on the use of morphine and fentanyl in
neonates has come from studies evaluating preterm infants
within the NICU, who were typically mechanically venti-
lated. Thus, one should be careful when extrapolating this
data to apply to a wider patient population including term
neonates who are not mechanically ventilated. However, as
noted before both morphine and fentanyl are commonly
used for procedural pain control. In regard to side effect
profile, hypotension has been associated with use of mor-
phine in preterm infants, which was not found in term
infants [65, 66].
Fentanyl provides rapid analgesia and has been well
established as effective for pain reduction in tracheal
intubation, chest tube insertion, incision and drainage, and
postoperative procedural pain [67]. Fentanyl is an optimal
choice in neonates because it has minimal hemodynamic
effects, including less hypotension. It also has less GI
dysmotility and urinary retention when compared with
morphine [68–71]. However, bradycardia and chest wall
rigidity are well-known side effects [72]. Further studies
are needed to evaluate its safety and efficacy in use for one-
time procedures. It should also be noted that alternative
routes of administration including transmucosal, aero-
solized, and inhaled fentanyl have demonstrated effec-
tiveness similar to intravenous opioids [73, 77]. In
mechanically ventilated neonates, fentanyl doses of 1–3
lg/kg are typically recommended to provide analgesia
[72]. In non-intubated patients, lower doses, such as 0.5–1
lg/kg of IV fentanyl may be more appropriate, although
further studies in this patient population are warranted.
Naloxone is an effective reversal agent for opioid anal-
gesics and should be readily available to reverse respiratory
depression or other complications when opioids are
Curr Emerg Hosp Med Rep (2016) 4:1–10 7
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used. Slow administration of fentanyl injections over
3–5 min decreases the potential for skeletal muscle/chest
wall rigidity and associated impaired ventilation, respira-
tory distress or even respiratory arrest. Nondepolarizing
skeletal muscle relaxants/paralytics such as rocuronium
1 mg/kg can be used to reverse chest wall rigidity but
require endotrachial intubation for manual and/or
mechanical ventilation, so prior preparation for potential
intubation recommended with fentanyl usage.
Ketamine
Ketamine, an NMDA receptor antagonist, also known as a
dissociative anesthetic, has come to favor more recently
with regards to procedural sedation. The literature of its use
in neonates is not as robust as literature supporting use in
older pediatric and adult populations. Ketamine is ideal as
it provides appropriate sedation, amnesia, and does not
have hemodynamic instability as other well-established
sedatives. Ketamine maintains respiratory drive, allows for
bronchodilation, which improves ventilation and hemody-
namic functioning, and has only minimal effects on heart
rate and blood pressure [72]. Recommended dosing, as
established in a subset of NICU neonates, is 1–2 mg/
kg/dose. Doses greater than 2 mg/kg/dose are associated
with reduction in heart rate [74]. The dose of 5 mg/kg has
been associated with reduced blood pressure without
impairing cardiac output [75].
Other Sedatives
Other sedative medications including anxiolytics such as
midazolam, dexmedetomidine, and inhaled nitrous oxide
have potential applications for use for painful procedures.
However, not enough research has been conducted to
establish their effectiveness at reducing pain in term neo-
nates or potential adverse medication effects.
Conclusion
As we noted, newborns experience pain as measured by
physiologic, behavioral, metabolic, and hormonal respon-
ses. They also experience long-term sequelae from pain
including impaired neurologic and behavioral develop-
ment. To date, there is no universal approach to neona-
tal pain assessment. Further, although there are guidelines
for management of neonatal pain in the NICU, this
approach has not translated to other venues where clini-
cians evaluate and treat neonates. We have reviewed val-
idated pain scoring systems, such as PIPP, FLACC, NIPS,
and DAN. Further, we recommend a tiered approach for
the management of neonatal pain, including environmental,
non-pharmacologic, and pharmacologic pain interventions.
With a standardized approach to assessing and managing
pain, we hope to improve acute neonatal pain, long-term
neurologic and behavioral outcomes, as well as parent and
provider satisfaction. Ultimately, further research is needed
regarding efficacy, safety profiles, and satisfaction scoring
to better achieve these goals.
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